To elucidate the potential mechanisms for TDP-43 aggregation and neurodegeneration in ALS patients that carry optineurin mutations, we generated optineurin targeting constructs and silenced this gene using a conventional CRISPR/Cas9 approach. The gene discussed is TARDBP; the disease is amyotrophic lateral sclerosis.